Vaccine studies at Cincinnati Children’s receive national attention as research tests are conducted between ages 5 and 11

Efforts to return to prepandemic norms take another step forward as vaccine studies are now moving into some of the youngest age groups. Cincinnati Children’s Hospital starts vaccination trials for children ages 5-11 on Monday, you see and see the safety profile and if that looks okay, drop to 2-5 years and then repeat. If that looks okay, you’re going to an even younger age, ”said Cincinnati Children’s Hospital Dr. Robert Frenck.Frenck directs the children’s studies. He led the Pfizer adult study and was also part of the AstraZeneca studies. France said the first aspects they want to look into are safety and dosage. “Adults receive 30 micrograms for the Pfizer. So for the children we start with 10 micrograms, then we evaluate that dose, then look at 20 micrograms and then possibly 30 micrograms, ”said Frenck. The studies receive national attention. Frenck appeared on MSNBC Friday to discuss the studies. Research on the age group from 5 to 11 years old starts small with just eight children before growing in the second phase. Across the country, only about 2,000 children are needed for the compared study, France said the numbers for children don’t have to be nearly as high because they only measure the immune response in children. When it agrees with the adults, they can extrapolate the information they need to compare it to adults and understand the effectiveness.

CINCINNATI –

Efforts to return to pre-pandemic norms take another step forward as vaccine studies are now moving into some of the youngest age groups.

Cincinnati Children’s Hospital will begin vaccination trials for children ages 5-11 on Monday.

“The plan would be for you to see and see the safety profile. If that looks okay, fall on 2 to 5 year olds and then repeat it. If that looks okay, move on to an even younger age.” said Cincinnati Children’s Hospital Dr. Robert Frenck.

Frenck directs the children’s studies. He led the Pfizer adult study and was also part of the AstraZeneca studies.

Frenck said the first aspects they want to look into are safety and dosage.

“Adults receive 30 micrograms for the Pfizer. So for the children we start with 10 micrograms, then we evaluate that dose and then look at 20 micrograms, then possibly 30 micrograms, ”said Frenck.

The studies receive national attention. Frenck appeared on MSNBC Friday to discuss the studies.

Research on the age group from 5 to 11 years old starts small with just eight children before growing in the second phase.

Across the country, only about 2,000 children are needed for the study, compared with about 30,000 adults.

Frenck said the numbers don’t have to be nearly as high for children because they only measure the immune response in children. When it agrees with the adults, they can extrapolate the information they need to compare it to adults and understand the effectiveness.